Scholarlink

<p>Currently, there are no approved first-line targeted inhibitors for ICC. ADAM8 is one of the most frequently over-expressed proteins in human intrahepatic cholangiocarcinoma (ICC). This review examines the potential of ADAM8 as a direct therapeutic target for ICC, emphasizing its downstream impact on Notch and Integrin signaling pathways. Collectively, these findings suggest ADAM8 may represent a novel strategy for ICC management. We have consolidated pre-clinical research on ADAM8 inhibitors, which demonstrate inhibitory effects on epithelial mesenchymal transition (EMT) and tumor angiogenesis by cleaving substrates such as CHL1 and CD23 to form their active fragments. And its substrate form may be monomers, dimers, or even polymers. This review provides a critical discussion of the therapeutic potential of ADAM8 inhibitors in ICC. However, further challenges remain, including enhancing inhibitor specificity, conducting long-term studies to thoroughly evaluate the benefits and risks associated with targeting ADAM8.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of ADAM8 in intrahepatic cholangiocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月9日

查看全文
  • Xilin Cui,
  • Ziyi Wang,
  • Chengkang Wang,
  • Muxuan Jiang,
  • Xiaoxuan Song,
  • Yujuan Liu,
  • Xinshan Deng,
  • Xiaoling Wang,
  • Yingshi Zhang

摘要

Currently, there are no approved first-line targeted inhibitors for ICC. ADAM8 is one of the most frequently over-expressed proteins in human intrahepatic cholangiocarcinoma (ICC). This review examines the potential of ADAM8 as a direct therapeutic target for ICC, emphasizing its downstream impact on Notch and Integrin signaling pathways. Collectively, these findings suggest ADAM8 may represent a novel strategy for ICC management. We have consolidated pre-clinical research on ADAM8 inhibitors, which demonstrate inhibitory effects on epithelial mesenchymal transition (EMT) and tumor angiogenesis by cleaving substrates such as CHL1 and CD23 to form their active fragments. And its substrate form may be monomers, dimers, or even polymers. This review provides a critical discussion of the therapeutic potential of ADAM8 inhibitors in ICC. However, further challenges remain, including enhancing inhibitor specificity, conducting long-term studies to thoroughly evaluate the benefits and risks associated with targeting ADAM8.